Vaquer Sergi, Chemla Denis, Teboul Jean-Louis, Ahmad Umar, Cipriani Flora, Oliva Joan Carles, Ochagavia Ana, Artigas Antonio, Baigorri Francisco, Monnet Xavier
Servei de Medicina Intensiva, Centre de Crítics, Corporació Sanitària Universitària Parc Taulí, Parc Taulí 1, 08208, Sabadell, Spain.
Departament de Medicina, Facultat de Medicina, Universitat Autònoma de Barcelona, Passeig de la Vall d´Hebron 119, 08035, Barcelona, Spain.
Ann Intensive Care. 2019 May 30;9(1):61. doi: 10.1186/s13613-019-0537-4.
Femoral dP/dt (maximum rate of the arterial pressure increase during systole) measured by pulse contour analysis has been proposed as a surrogate of left ventricular (LV) dP/dt and as an estimator of LV systolic function. However, femoral dP/dt may be influenced by LV loading conditions. In this study, we evaluated the impact of variations of LV systolic function, preload and afterload on femoral dP/dt in critically ill patients with cardiovascular failure to ascertain its reliability as a marker of LV systolic function.
We performed a prospective observational study to evaluate changes in femoral dP/dt, thermodilution-derived variables (PiCCO2-Pulsion Medical Systems, Feldkirchen, Germany) and LV ejection fraction (LVEF) measured by transthoracic echocardiography during variations in dobutamine and norepinephrine doses and during volume expansion (VE) and passive leg raising (PLR). Correlations with arterial pulse and systolic pressure, effective arterial elastance, total arterial compliance and LVEF were also evaluated. In absolute values, femoral dP/dt deviated from baseline by 21% (201 ± 297 mmHg/s; p = 0.013) following variations in dobutamine dose (n = 17) and by 15% (177 ± 135 mmHg/s; p < 0.001) following norepinephrine dose changes (n = 29). Femoral dP/dt remained unchanged after VE and PLR (n = 24). Changes in femoral dP/dt were strongly correlated with changes in pulse pressure and systolic arterial pressure during dobutamine dose changes (R = 0.942 and 0.897, respectively), norepinephrine changes (R = 0.977 and 0.941, respectively) and VE or PLR (R = 0.924 and 0.897, respectively) (p < 0.05 in all cases). Changes in femoral dP/dt were correlated with changes in LVEF (R = 0.527) during dobutamine dose variations but also with effective arterial elastance and total arterial compliance in the norepinephrine group (R = 0.638 and R = - 0.689) (p < 0.05 in all cases).
Pulse contour analysis-derived femoral dP/dt was not only influenced by LV systolic function but also and prominently by LV afterload and arterial waveform characteristics in patients with acute cardiovascular failure. These results suggest that femoral dP/dt calculated by pulse contour analysis is an unreliable estimate of LV systolic function during changes in LV afterload and arterial load by norepinephrine and directly linked to arterial waveform determinants.
通过脉搏轮廓分析测量的股动脉dP/dt(收缩期动脉压升高的最大速率)已被提议作为左心室(LV)dP/dt的替代指标和LV收缩功能的估计值。然而,股动脉dP/dt可能受LV负荷条件的影响。在本研究中,我们评估了LV收缩功能、前负荷和后负荷变化对心血管衰竭重症患者股动脉dP/dt的影响,以确定其作为LV收缩功能标志物的可靠性。
我们进行了一项前瞻性观察性研究,以评估在多巴酚丁胺和去甲肾上腺素剂量变化期间以及容量扩张(VE)和被动抬腿(PLR)期间,通过经胸超声心动图测量的股动脉dP/dt、热稀释衍生变量(PiCCO2 - Pulsion Medical Systems,德国费尔德kirchen)和LV射血分数(LVEF)的变化。还评估了与动脉脉搏和收缩压、有效动脉弹性、总动脉顺应性和LVEF的相关性。绝对值方面,多巴酚丁胺剂量变化后(n = 17),股动脉dP/dt较基线偏离21%(201±297mmHg/s;p = 0.013),去甲肾上腺素剂量变化后(n = 29),股动脉dP/dt较基线偏离15%(177±135mmHg/s;p < 0.001)。VE和PLR后股动脉dP/dt保持不变(n = 24)。在多巴酚丁胺剂量变化期间(分别为R = 0.942和0.897)、去甲肾上腺素变化期间(分别为R = 0.977和0.941)以及VE或PLR期间(分别为R = 0.924和0.897),股动脉dP/dt的变化与脉压和收缩期动脉压的变化密切相关(所有情况下p < 0.05)。在多巴酚丁胺剂量变化期间,股动脉dP/dt的变化与LVEF的变化相关(R = 0.527),但在去甲肾上腺素组中也与有效动脉弹性和总动脉顺应性相关(R = 0.638和R = - 0.689)(所有情况下p < 0.05)。
在急性心血管衰竭患者中,脉搏轮廓分析得出的股动脉dP/dt不仅受LV收缩功能影响,还显著受LV后负荷和动脉波形特征影响。这些结果表明,通过脉搏轮廓分析计算的股动脉dP/dt在LV后负荷和去甲肾上腺素引起的动脉负荷变化期间,是LV收缩功能的不可靠估计值,并且与动脉波形决定因素直接相关。